ISSN:
1573-7217
Keywords:
aromatase
;
aromatase inhibitors
;
breast cancer
;
estrogen
;
estrous cycle
;
tumor regression
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary The aromatase inhibitor 10-propargylestr-4-ene-3,17-dione (PED) has been evaluatedin vivo as an anticancer agent. Prolonged administration of PED to rats bearing dimethylbenzanthracene-induced mammary tumors resulted in significant regression of hormone-responsive tumors within several days. Greater than 50% regression was generally observed after 14 days of treatment, irrespective of dose (1, 5, or 50mg/kg body weight/day). In addition to tumor regression, a significantly increased incidence in tumor stasis was observed over the course of PED treatment. While all doses of PED examined were equipotent for both tumor regression and stasis, a dose-dependent inhibition of new tumor formation was observed in PED-treated rats. In control animals an average of 1.2 new tumors was observed during the experimental period; in contrast, averages of 0.5 tumors appeared in animals receiving 1mg PED/kg body weight/day, 0.1 tumors at 5 mg/kg, and at 50mg of PED/kg body weight/day, no new tumors occurred during the time PED was administered. The effects of PED on both regression of existing tumors and appearance of new tumors were reversed by co-administration of estradiol. Thus, PED impairs estrogen-dependent mammary tumor growth, resulting in cessation of new growth and regression of responsive tumors.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00682696
Permalink
